Ohio Department of Medicaid
(ODM) Drug Utilization Review
(DUR) Board Quarterly Meeting
May 8, 2018

The quarterly meeting of the ODM DUR Board was called to order at 12:04 PM EST in room C621 A&B, 50 West Town Street, Columbus, Ohio. Donald Sullivan, R.Ph. presided.

The following Board members were present:
David Brookover, R.Ph.
Michael Dietz, D.O.
Robert Kubasak, R.Ph.
Donald Sullivan, R.Ph.

Also present from ODM were Tracey Archibald, Pharm. D., DUR Administrator, and Michelle Barger, Pharm.D. Change Healthcare attendees included Benjamin Link, Pharm.D., Jill RK Griffith, Pharm.D., and Gail Master, R.Ph. Approximately 17 observers were present, most representing pharmaceutical manufacturers.

Roll Call, Reading, Correction, and Approval of previous Minutes

The February 6, 2018, DUR Board Meeting minutes were approved.

DUR Committee Report

G. Master presented a summary on retrospective drug utilization review (RetroDUR) interventions focusing on proton pump inhibitors. Discussion ensued regarding the results of the intervention particularly around the response rate. Suggestions for improving response by modifying letters was provided. The Board decided that the results of the intervention would be measured and the DUR Committee should focus efforts on new interventions.

G. Master and T. Archibald presented a summary of a new intervention around Medication-Assisted Treatment for substance use disorder and concurrent opioid use. T. Archibald reviewed the draft protocol for how this longitudinal intervention would be undertaken by ODM APPE pharmacy students. The Board reviewed the protocol and requested clarification around use of the Ohio Automated RX Reporting System reports. The Board indicated they were in agreement that the Department should proceed with the intervention.

G. Master presented a potential intervention targeting members on long-term muscle relaxants. Discussion ensued, and it was acknowledged that the intervention needed to be educational in nature.

G. Master reviewed the tentative RetroDUR calendar for the coming year.

G. Master reviewed the Coordinated Services Program (CSP) and results for the program thus far.

Health Plan Policy

T. Archibald announced that the Single Preferred Drug List (S-PDL) has been delayed until January 1, 2019. S-PDL will be phased in with three selected therapeutic categories aligning every six months. At this time the categories have not yet been finalized. It was also announced that the minutes from the last P&T Committee meeting are posted to the website.

T. Archibald announced that the Request for Letters of Interest for DUR Committee pharmacists was posted on the Department of Administrative Services (DAS) website. There are currently six openings. The DUR Board requested that information be forwarded to them. There is also one DUR Board opening for a pharmacist.

T. Archibald announced that ODM was in the process of reviewing Request for Proposal responses for the cost of dispensing survey required to be conducted every two years. A vendor will be selected and in summer the surveys will be distributed to the pharmacies.

Unfinished Business

There was no unfinished

business. New Business

G. Master discussed an intervention to target prescribers who have patients on opioid therapy greater than 400 Morphine Equivalent Daily Doses. The goal of the intervention is to provide educational resources to prescribers. Discussion ensued regarding the letter format.

G. Master reviewed the DUR Digest. The Board suggested that a section of the Digest provide an overview of a PDL therapeutic category rather than an overview of the program spend and utilization information.

B. Link reviewed the proposal for changes to chemotherapeutic agents. It was identified that as part of the process to work towards a S-PDL this change to the fee-for-service program was being suggested to align managed care and fee-for-service prior authorization criteria. Discussion ensued, and the Board decided to table the discussion at this time.

B. Link reviewed the proposal for intervening on levetiracetam doses exceeding 3,000 mg per day. It was discussed that the goal of the edit was to obtain information about the rationale for high dose prescribing. The Board suggested that a specialist be consulted and made some recommendations.

Announcements

The dates for the next DUR Board meetings are: Tuesday, September 11th and Tuesday, November 13th at 12 pm.

Adjournment

Donald Sullivan, R.Ph. adjourned the meeting at 1:13 P.M.